Literature DB >> 10867799

Aciculin and its relation to dystrophin: immunocytochemical studies in human normal and Duchenne dystrophy quadriceps muscles.

Y Wakayama1, M Inoue, H Kojima, M Murahashi, S Shibuya, S Yamashita, H Oniki.   

Abstract

Aciculin is a novel adherens junction antigen extracted from human uterine smooth muscle that is reported to associate biochemically with dystrophin. We attempted to determine (i) the immunostainability of anti-aciculin antibody for the 6 histochemically normal human muscles and seven muscles from boys with Duchenne muscular dystrophy (DMD) and 11 disease control muscles, (ii) the ultrastructural localization of aciculin in normal skeletal myofibers, (iii) aciculin's spacial relationship with dystrophin and beta-spectrin, and (iv) if the aciculin is ultrastructurally colocalized with dystrophin, the distance from the aciculin epitope to the epitope of the dystrophin N- or C-terminal domain. For this, rabbit anti-aciculin antibody was generated against the synthetic peptide of aciculin fragment D [4]. Immunohistochemical staining showed that the immunostainability of DMD muscles for anti-aciculin antibody was markedly decreased as compared with normal and disease control muscles. Single and double immunogold labeling electron microscopy of 6 histochemically normal human quadriceps femoris muscles revealed that aciculin was present along the inner surface of muscle plasma membrane and that aciculin formed doublets more frequently with dystrophin (23.5 +/- 1.8%; group mean +/- SE) than with beta-spectrin (12.8 +/- 1.1%; P < 0.01 two tailed t test). Rabbit anti-aciculin antibody frequently formed doublets with monoclonal antibodies against the N- or C-terminal domain of dystrophin at the muscle cell surface. These results suggest that aciculin is associated with dystrophin and may interact with both the N- and C-terminal domains of dystrophin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867799     DOI: 10.1007/s004010051176

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  5 in total

1.  Downregulation of PGM5 expression correlates with tumor progression and poor prognosis in human prostate cancer.

Authors:  Jian Sun; Fei Wang; Huihui Zhou; Chunchun Zhao; Kai Li; Caibin Fan; Jianqing Wang
Journal:  Discov Oncol       Date:  2022-07-12

2.  A discovery resource of rare copy number variations in individuals with autism spectrum disorder.

Authors:  Aparna Prasad; Daniele Merico; Bhooma Thiruvahindrapuram; John Wei; Anath C Lionel; Daisuke Sato; Jessica Rickaby; Chao Lu; Peter Szatmari; Wendy Roberts; Bridget A Fernandez; Christian R Marshall; Eli Hatchwell; Peggy S Eis; Stephen W Scherer
Journal:  G3 (Bethesda)       Date:  2012-12-01       Impact factor: 3.154

3.  PGM5: a novel diagnostic and prognostic biomarker for liver cancer.

Authors:  Yan Jiao; Yanqing Li; Peiqiang Jiang; Wei Han; Yahui Liu
Journal:  PeerJ       Date:  2019-06-11       Impact factor: 2.984

4.  Identification of Novel Regulatory Genes in APAP Induced Hepatocyte Toxicity by a Genome-Wide CRISPR-Cas9 Screen.

Authors:  Katherine Shortt; Daniel P Heruth; NiNi Zhang; Weibin Wu; Shipra Singh; Ding-You Li; Li Qin Zhang; Gerald J Wyckoff; Lei S Qi; Craig A Friesen; Shui Qing Ye
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

5.  PGM5 is a promising biomarker and may predict the prognosis of colorectal cancer patients.

Authors:  Yifan Sun; Haihua Long; Lin Sun; Xiujuan Sun; Liping Pang; Jianlin Chen; Qingqun Yi; Tianwei Liang; Yongqi Shen
Journal:  Cancer Cell Int       Date:  2019-10-01       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.